According to the fourth World Health Organization (WHO) on neglected tropical diseases (NTD), India has achieved the target for the elimination of visceral leishmaniasis (kala azar) in 82% sub-districts and the government has set a target of eliminating visceral leishmaniasis by 2017 and lymphatic filariasis in endemic pockets by 2017. Another significant achievement was the elimination of yaws, a chronic skin disease that mostly affects poor children, in 2015. WHO India as the first member state to “achieve this important milestone”. India has also progressed well in treating lymphatic filariasis (elephantiasis), and has stopped mass drug administration in 72 endemic districts after passing evaluations.
The BioSpectrum India edition was launched in March 2003 and is India's first comprehensive biotech business monthly magazine. It provides comprehensive coverage of the exciting happenings in life sciences, which include BioPharma, BioAgriculture, BioInformatics, BioIndustrial, BioSuppliers and BioServices and show cases the emerging Indian entrepreneurships in biotech industry. In a short time BioSpectrum has emerged as the most preferred platform to engage the life sciences industry in India and Asia Pacific. It is also widely accepted by research and academia community. Top key policy makers in the Central and state government use the magazine as a platform to reach out the Indian Biotech Industry. BioSpectrum has columns by Indian's top policy makers, biotechnology professionals, scientists and NGOs. Readers of BioSpectrum are from among the key Policy Makers, Key Executives and the Influencer's in Biotechnology, Pharmaceutical Companies, Research Heads of Clinical Research, Clinical Trials and Contract Mfg Organizations, Educational Institutes, Consultants, Fund Managers etc